Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Could SBS-147 become a credible challenger to opioid-based pain management pathways? Could SBS-147 challenge opioid-based pain treatment pathways? Read how Sparian Biosciences’ Phase 1 launch could reshape the non-opioid market. bySoujanya RaviApril 12, 2026